U.S. Markets open in 2 hrs 13 mins
  • S&P Futures

    3,424.25
    -27.50 (-0.80%)
     
  • Dow Futures

    27,952.00
    -237.00 (-0.84%)
     
  • Nasdaq Futures

    11,589.25
    -74.25 (-0.64%)
     
  • Russell 2000 Futures

    1,617.60
    -18.00 (-1.10%)
     
  • Crude Oil

    39.12
    -0.73 (-1.83%)
     
  • Gold

    1,906.90
    +1.70 (+0.09%)
     
  • Silver

    24.42
    -0.25 (-1.01%)
     
  • EUR/USD

    1.1826
    -0.0042 (-0.3548%)
     
  • 10-Yr Bond

    0.8410
    0.0000 (0.00%)
     
  • Vix

    29.71
    +1.60 (+5.69%)
     
  • GBP/USD

    1.3062
    +0.0024 (+0.1842%)
     
  • USD/JPY

    104.8620
    +0.1720 (+0.1643%)
     
  • BTC-USD

    13,161.09
    +84.07 (+0.64%)
     
  • CMC Crypto 200

    263.82
    +2.37 (+0.91%)
     
  • FTSE 100

    5,850.18
    -10.10 (-0.17%)
     
  • Nikkei 225

    23,494.34
    -22.25 (-0.09%)
     

PolarityTE Reports Second Quarter 2020 Results

·9 mins read

PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the second calendar quarter of 2020. PolarityTE will host a conference call and webcast today, August 6, 2020 at 8:00 a.m. ET.

Highlights

  • Total revenues were $2.27 million in Q2:20 compared to $1.33 million in Q2:19

  • SkinTE revenues were $0.94 million in Q2:20 compared to $0.50 million in Q2:19

  • Paid Cases were 88 in Q2:20 compared to 46 in Q2:19

Financial Results for the Three Months Ended June 30, 2020

Total revenue for the three months ended June 30, 2020 was $2.27 million, of which $0.94 million was from sales of SkinTE and $1.32 million from PolarityTE’s contract service operations, which includes $0.71 million from COVID-19 testing services that the Company started providing at the end of May 2020.

Research and development expenses for the three months ended June 30, 2020 were approximately $3.16 million versus $4.76 million for the three months ended June 30, 2019. Research and development expenses for the three months ended June 30, 2020 included an expense of $0.40 million from stock-based compensation which is a non-cash charge, versus $1.48 million for the three months ended June 30, 2019.

General and administrative expenses for the three months ended June 30, 2020 were $5.21 million versus $15.06 million for the three months ended June 30, 2019. General and administrative expenses for the three months ended June 30, 2020 included $0.14 million of stock-based compensation which is a non-cash charge, versus $6.89 million for the three months ended June 30, 2019.

Sales and marketing expenses for the three months ended June 30, 2020 were $2.02 million versus $3.98 million for the three months ended June 30, 2019.

Net loss for the three months ended June 30, 2020 was $12.68 million compared with a net loss of $22.79 million for the three months ended June 30, 2019.

Cash and Liquidity as of June 30, 2020

As of June 30, 2020, our cash, cash equivalents and short-term investments balance was approximately $30.50 million, compared to cash and cash equivalents and short-term investments of $29.24 million at December 31, 2019.

Cash used in operating activities for the three-month period ended June 30, 2020 was approximately $11.56 million, or approximately $3.85 million per month on average, 10% lower than the $4.27 million monthly average in the three months ended June 30, 2019 and 17% lower than the $4.62 million monthly average in the three months ended March 31, 2020.

The Company believes capital resources will be sufficient to fund its current business plan including related operating expenses and capital expenditure requirements into the second quarter of 2021.

Conference Call and Webcast Details

The conference call can be accessed by calling 1-888-599-8688 (U.S. and Canada) or +44 (0)330 336 9104 (International), with confirmation code 679989 and referencing "PolarityTE Second Quarter 2020 Earnings Call." A webcast of the conference call can be accessed by using the link below.

Earnings Call Webcast – CLICK HERE

A replay of the earnings conference call will be available for 30 days, beginning approximately one hour after the conclusion of the call and can be found by visiting PolarityTE’s website at https://www.polarityte.com/news-media/events or by clicking on the link above.

About PolarityTE®

PolarityTE is focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures products from the patient's own tissue and uses the patient's own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to regenerate the target tissues. PolarityTE's innovative methods are intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift®.

Forward Looking Statements

Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to the impact of the COVID-19 pandemic and FDA regulatory matters, which cannot be predicted, and the risk factors and other items described in more detail in the "Risk Factors" section of the Company's annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).

POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are trademarks or registered trademarks of PolarityTE, Inc.

POLARITYTE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, in thousands, except share and per share amounts)

June 30,
2020

December 31,
2019

ASSETS

Current assets

Cash and cash equivalents

$

30,504

$

10,218

Short-term investments

19,022

Accounts receivable, net

2,115

1,731

Inventory

281

252

Prepaid expenses and other current assets

2,453

1,264

Total current assets

35,353

32,487

Property and equipment, net

12,729

14,911

Operating lease right-of-use assets

3,559

4,590

Intangible assets, net

636

731

Goodwill

278

278

Other assets

599

602

TOTAL ASSETS

$

53,154

$

53,599

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities

Accounts payable and accrued expenses

$

5,050

$

7,095

Other current liabilities

2,644

2,338

Current portion of long-term notes payable

1,436

528

Deferred revenue

97

98

Total current liabilities

9,227

10,059

Common stock warrant liability

8,736

Operating lease liabilities

2,192

2,994

Other long-term liabilities

1,022

1,630

Long-term notes payable

2,410

Total liabilities

23,587

14,683

STOCKHOLDERS’ EQUITY

Preferred stock - 25,000,000 shares authorized, 0 shares issued and outstanding at June 30, 2020 and December 31, 2019

Common stock – $.001 par value; 250,000,000 shares authorized; 38,496,910 and 27,374,653 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively

38

27

Additional paid-in capital

490,603

474,174

Accumulated other comprehensive income

72

Accumulated deficit

(461,074

)

(435,357

)

Total stockholders’ equity

29,567

38,916

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

53,154

$

53,599

POLARITYTE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, in thousands, except share and per share amounts)

For the Three Months Ended

For the Six Months Ended

June 30,

June 30,

2020

2019

2020

2019

Net revenues

Products

$

944

$

504

$

1,372

$

801

Services

1,322

822

1,827

1,990

Total net revenues

2,266

1,326

3,199

2,791

Cost of sales

Products

275

342

615

615

Services

607

254

783

757

Total cost of sales

882

596

1,398

1,372

Gross profit

1,384

730

1,801

1,419

Operating costs and expenses

Research and development

3,164

4,764

6,537

10,116

General and administrative

5,211

15,060

15,816

32,255

Sales and marketing

2,024

3,981

5,718

7,934

Restructuring and other charges

2,084

2,536

Total operating costs and expenses

12,483

23,805

30,607

50,305

Operating loss

(11,099

)

(23,075

)

(28,806

)

(48,886

)

Other income (expenses)

Change in fair value of common stock warrant liability

(1,591

)

2,941

Interest (expense) income, net

(65

)

29

(77

)

99

Other income, net

78

254

225

422

Net loss

$

(12,677

)

$

(22,792

)

$

(25,717

)

$

(48,365

)

Net loss per share, basic and diluted

$

(0.33

)

$

(0.92

)

$

(0.72

)

$

(2.09

)

Weighted average shares outstanding, basic and diluted

38,428,289

24,768,453

35,724,141

23,190,343

POLARITYTE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)

For the Six Months Ended
June 30,

2020

2019

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss

$

(25,717

)

$

(48,365

)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock based compensation expense

3,784

18,907

Depreciation and amortization

1,549

1,446

Amortization of intangible assets

95

99

Amortization of debt discount

13

28

Change in fair value of common stock warrant liability

(2,941

)

Change in fair value of contingent consideration

(48

)

Loss on abandonment of property and equipment

1,529

Other non-cash adjustments

(21

)

30

Changes in operating assets and liabilities:

Accounts receivable

(384

)

(624

)

Inventory

(29

)

(26

)

Prepaid expenses and other current assets

(1,189

)

(486

)

Operating lease right-of-use assets

899

791

Other assets

3

25

Accounts payable and accrued expenses

(2,109

)

(17

)

Other current liabilities

9

367

Deferred revenue

(1

)

(126

)

Operating lease liabilities

(903

)

(670

)

Other long-term liabilities

(120

)

Net cash used in operating activities

(25,413

)

(28,789

)

CASH FLOWS FROM INVESTING ACTIVITIES

Purchase of property and equipment

(1,170

)

(2,110

)

Purchase of available-for-sale securities

(14,144

)

(15,445

)

Proceeds from maturities of available-for-sale securities

16,945

9,278

Proceeds from sale of available-for-sale securities

16,171

Net cash provided by (used in) investing activities

17,802

(8,277

)

CASH FLOWS FROM FINANCING ACTIVITIES

Net proceeds from the sale of common stock and warrants

24,276

27,948

Proceeds from stock options exercised

31

529

Proceeds from ESPP purchase

40

35

Cash paid for tax withholdings related to net share settlement

(6

)

(636

)

Payment of contingent consideration liability

(109

)

Principal payments on financing leases

(243

)

(225

)

Proceeds from term note payable and financing arrangements

4,629

Principal payments on term note payable and financing arrangements

(830

)

(262

)

Net cash provided by financing activities

27,897

27,280

Net increase (decrease) in cash and cash equivalents

20,286

(9,786

)

Cash and cash equivalents - beginning of period

10,218

55,673

Cash and cash equivalents - end of period

$

30,504

$

45,887

View source version on businesswire.com: https://www.businesswire.com/news/home/20200806005238/en/

Contacts

Investors:
Rich Haerle
VP, Investor Relations
PolarityTE, Inc.
ir@PolarityTE.com
(385) 315-0697